FDA approves EMCITATE (tiratricol), the first treatment for MCT8 deficiency, targeting peripheral thyrotoxicosis in adults and children.
Written By: Siddhi Bhadekar, M. Pharm (QA)
Reviewed By: Pharmacally Editorial Team
On September 28, 2026, Egetis Therapeutics AB announced that the U.S. Food and Drug Administration (FDA) approved EMCITATE® (tiratricol) for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan-Herndon-Dudley syndrome (AHDS).
The FDA described EMCITATE as the first treatment approved for MCT8 deficiency. The product is supplied as tablets for oral suspension and is administered once daily. The approval specifically targets the peripheral thyrotoxicosis associated with the disorder and is not intended to treat its neurological manifestations.
Regulatory Significance
EMCITATE received Orphan Drug, Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations during development and was reviewed under Priority Review. The FDA also granted Egetis a Rare Pediatric Disease Priority Review Voucher in connection with the approval.
The U.S. authorization follows marketing authorization for EMCITATE in the European Union.
How EMCITATE Works
MCT8 is a thyroid hormone transporter encoded by the SLC16A2 gene. Pathogenic variants that impair MCT8 function disrupt thyroid hormone transport, particularly into the brain.
Tiratricol is a thyroid hormone receptor agonist that can enter cells independently of the defective MCT8 transporter. By bypassing the transporter defect, it reduces the excessive peripheral effects of thyroid hormone associated with MCT8 deficiency.
EMCITATE is administered once daily as a suspension prepared from tablets and can be given orally or through a feeding tube. Patients taking another thyroid medication should consult their healthcare provider before starting treatment because the therapies should not be combined.
MCT8 Deficiency and Peripheral Thyrotoxicosis
MCT8 deficiency is an X-linked disorder caused by pathogenic variants in SLC16A2 and predominantly affects males. Impaired MCT8 function limits thyroid hormone transport into the brain, resulting in insufficient thyroid hormone activity in the central nervous system while T3 accumulates in the circulation and peripheral tissues.
Patients can develop severe neurodevelopmental impairment alongside persistent peripheral thyrotoxicosis, with manifestations including feeding difficulties, impaired growth, muscle wasting and cardiovascular abnormalities. Many affected patients have severe intellectual disability, limited or absent speech, and impaired ability to sit or walk independently.
Clinical Evidence Supporting Approval
The EMCITATE development program included ReTRIACt, Triac Trial I, Triac Trial II, the Erasmus Medical Center Cohort Study, the EMC Survival Study and a U.S. Expanded Access Program.
The FDA highlighted two studies involving patients from infancy to adulthood: an international, multicenter, randomized, placebo-controlled study and a longer-term open-label study. According to the FDA, treatment reduced excess circulating thyroid hormone levels and improved thyroid-sensitive cardiovascular and metabolic measures, including systolic blood pressure and heart rate.
ReTRIACt was a randomized, placebo-controlled withdrawal study evaluating continued tiratricol treatment versus withdrawal in patients receiving stable therapy. The study used serum total T3 as an important biochemical marker.
Triac Trial II evaluated tiratricol in young boys with MCT8 deficiency, assessing neurodevelopmental and peripheral thyroid hormone outcomes. The prespecified primary neurodevelopmental endpoints were not met, although secondary findings demonstrated sustained reductions in serum T3. This distinction is important because the FDA indication focuses on peripheral thyrotoxicosis, rather than established neurological impairment.
Safety Profile
EMCITATE carries a boxed warning stating that it is not indicated for obesity or weight loss, while primary hyperthyroidism is a contraindication. Signs of thyrotoxicosis, including increased heart rate, elevated blood pressure, diarrhea, hyperhidrosis, irritability, insomnia and nightmares, may occur during treatment initiation and dose titration.
Tiratricol can also interfere with certain T3 immunoassays, potentially producing unreliable or overestimated results. Reported adverse reactions occurring in at least 5% of patients included diarrhea, vomiting, rash and hyperhidrosis.
Patient Access
Egetis has launched Egetis RareLink™, a patient-support program developed with PANTHERx® Rare to support specialty distribution, medication access, education and care coordination. The company expects U.S. commercial availability approximately eight to 10 weeks after approval.
The FDA approval provides the first U.S.-approved treatment specifically targeting the peripheral thyrotoxicosis component of MCT8 deficiency, while the neurological manifestations of this rare genetic disorder remain an important area of unmet medical need.
Reference
Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE® (tiratricol) for Patients with MCT8 Deficiency, Egetis Therapeutics, 28 September 2026
About the Writer
Siddhi Rajendra Bhadekar (Linkedin) is an M.Pharm professional with expertise in medical and scientific writing, literature review, publication writing, and evidence synthesis, supported by four peer-reviewed publications.
She brings working knowledge of ICH-GCP, MedDRA, pharmacovigilance, ADR/AE reporting, clinical data management, and regulatory documentation.
With experience across pharmaceutical R&D, Quality Control, and Quality Assurance, she combines scientific research skills with strong attention to accuracy and detail.
Her background in manuscript development, publication planning, and scientific communication enables her to translate complex healthcare information into clear, reliable content.